Charles River Laboratories stock trades below its yearly high
📉 Charles River Laboratories reported Q2 revenue of USD 1 billion, down 2.7 percent year over year.
💰 Adjusted EPS beat consensus by USD 0.25, reaching USD 3.02 against an estimate of USD 2.77.
🏆 Evercore ISI lifted its price target to USD 320 while maintaining an Outperform rating.
📊 The stock traded at USD 285.94 on September 23, 2026, up 0.29 percent intraday.
🎯 Fiscal 2026 adjusted EPS guidance is set between USD 11.15 and USD 11.45.
📈 The company maintains a market capitalization of approximately USD 13.77 billion.
📉 Year-over-year EPS declined by USD 0.10 despite the earnings beat on adjusted metrics.
Bullish Signals
- Adjusted EPS beat consensus estimates by USD 0.25, reaching USD 3.02 against an expected USD 2.77.
- Evercore ISI maintained an Outperform rating and lifted its price target from USD 300 to USD 320.
- The stock traded near the upper end of its yearly range at USD 285.94, just 5.7 percent below its 52-week high.
Risk Factors
- Q2 revenue fell 2.7 percent year over year to USD 1 billion.
- Year-over-year EPS declined by USD 0.10 despite the adjusted earnings beat, highlighting margin pressure or cost challenges.
- The stock remains 5.7 percent below its 52-week high of USD 303.31 as of September 23, 2026.
Full Analysis
Charles River Laboratories International reported second-quarter results on August 5, 2026, showing a divergence between top-line revenue and earnings performance. The company generated USD 1 billion in revenue, representing a 2.7 percent year-over-year decline, while adjusted earnings per share (EPS) beat consensus estimates by USD 0.25 to reach USD 3.02 against an expected USD 2.77.
Despite the revenue contraction, the company successfully converted a smaller top line into adjusted earnings that exceeded market expectations. However, the year-over-year EPS decline of USD 0.10 keeps cost control and demand recovery central to the ongoing valuation discussion for this contract research organization.
Following the earnings release, Evercore ISI maintained an Outperform rating on September 11, 2026, lifting its price target from USD 300 to USD 320. As of September 23, 2026, the stock traded at USD 285.94, placing it near the upper end of its yearly range but still 5.7 percent below its 52-week high.
Analysts are focusing on the company's ability to sustain profitability amidst sales declines, with fiscal 2026 adjusted EPS guidance ranging between USD 11.15 and USD 11.45 providing a clear earnings yardstick for investors evaluating the stock's trajectory.
